Epithelioid glioblastoma

What it is

Epithelioid glioblastoma is a rare variant of glioblastoma defined by a distinctive cell appearance (epithelioid, meaning resembling epithelial cells). Notably, it often carries a BRAF V600E mutation, which can open the option of targeted therapy.

Understanding Epithelioid glioblastoma

This rare variant is recognized by its distinctive cells under the microscope and tends to occur in younger patients than typical glioblastoma. Its most practically important feature is that a substantial portion of these tumors carry the BRAF V600E mutation — a targetable change. This means that, in addition to standard treatment (surgery, radiation, and chemotherapy), BRAF-targeted therapy (BRAF inhibitors, often with MEK inhibitors) may be considered for BRAF V600E-positive cases. Testing for BRAF V600E is therefore particularly relevant in this variant. Recognizing epithelioid glioblastoma and its BRAF status can thus influence treatment. Understanding epithelioid glioblastoma clarifies a rare variant whose frequent BRAF mutation may allow targeted treatment.

Why it matters

Understanding epithelioid glioblastoma helps patients and families see a rare variant whose frequent BRAF V600E mutation matters — it may open the option of targeted therapy alongside standard treatment.